Sabby Management’s COSCIENS Biopharma CSCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
– Sell
-2,442
Closed -$214K – 204
2021
Q2
$214K Sell
2,442
-3,542
-59% -$337K 0.03% 131
2021
Q1
$682K Buy
+5,984
New +$663K 0.13% 93
2020
Q1
– Sell
-1,020
Closed -$93K – 108
2019
Q4
$93K Buy
1,020
+299
+41% +$27.9K 0.03% 61
2019
Q3
$74K Buy
721
+593
+463% +$128K 0.04% 77
2019
Q2
$38K Buy
+128
New +$45.1K 0.05% 80
2017
Q3
– Sell
-673
Closed -$67K – 213
2017
Q2
$67K Buy
+673
New +$107K ﹤0.01% 200
2017
Q1
– Sell
-4,006
Closed -$1.18M – 324
2016
Q4
$1.44M Buy
4,006
+3,336
+498% +$1.24M 0.08% 128
2016
Q3
$230K Sell
670
-1,988
-75% -$697K 0.01% 269
2016
Q2
$867K Sell
2,658
-2,267
-46% -$816K 0.05% 171
2016
Q1
$1.64M Sell
4,925
-416
-8% -$137K 0.08% 120
2015
Q4
$2.39M Buy
+5,341
New +$3.35M 0.13% 108

Other funds holding CSCI

Sabby Management's CSCI Position: Q3 2021 in Review

Sabby Management sold out of COSCIENS Biopharma (CSCI) in Q3 2021, closing a stake of 2,442 shares — an estimated $214K sold.

Sabby Management first reported a position in CSCI in Q4 2015 and held it in 11 quarters. The position peaked at $2.39M in Q4 2015. 31 funds tracked by Wall St. Rank hold CSCI as of Q3 2021.

  • Sabby Management reported no remaining COSCIENS Biopharma position as of Q3 2021 after selling out during the quarter.
  • Sabby Management sold 2,442 COSCIENS Biopharma shares in Q3 2021, an estimated $214K.
  • Sabby Management first reported a position in COSCIENS Biopharma in Q4 2015 and held it in 11 quarters.
  • Sabby Management's COSCIENS Biopharma position peaked at $2.39M in Q4 2015.
  • 31 funds tracked by Wall St. Rank held COSCIENS Biopharma as of Q3 2021.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.